Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy

Abdulrahman F. Al-Mashdali, Mujahid O. Abdelraof, Monia Ibrahim, Mohammed Abdulgayoom, Shehab F. Mohamed, Honar Cherif

Open source

DOI
10.1177/20406207261484097
Published
2026-08
Container
Therapeutic Advances in Hematology
Publisher
SAGE Publications
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/20406207261484097,
  title = {Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy},
  author = {Abdulrahman F. Al-Mashdali and Mujahid O. Abdelraof and Monia Ibrahim and Mohammed Abdulgayoom and Shehab F. Mohamed and Honar Cherif},
  year = {2026},
  journal = {Therapeutic Advances in Hematology},
  doi = {10.1177/20406207261484097},
  url = {https://doi.org/10.1177/20406207261484097}
}

RIS

TY  - JOUR
TI  - Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy
AU  - Abdulrahman F. Al-Mashdali
AU  - Mujahid O. Abdelraof
AU  - Monia Ibrahim
AU  - Mohammed Abdulgayoom
AU  - Shehab F. Mohamed
AU  - Honar Cherif
PY  - 2026
JO  - Therapeutic Advances in Hematology
DO  - 10.1177/20406207261484097
UR  - https://doi.org/10.1177/20406207261484097
ER  - 

APA

Al-Mashdali, A. F., Abdelraof, M. O., Ibrahim, M., Abdulgayoom, M., Mohamed, S. F., & Cherif, H. (2026). Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy. Therapeutic Advances in Hematology. https://doi.org/10.1177/20406207261484097

Source records